Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

FDA weighs new deputy commissioner posts; Trump set to reveal more MFN drug pricing deals

27 August 2026 · By · Wire by Fusion42

Published

27 August 2026

Topic

regulatory

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at raps.org →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

The US Department of Health and Human Services plans to create new deputy commissioner roles at the FDA focused on technology and drugs, while former President Trump is preparing to announce new most-favored-nation (MFN) drug pricing deals with mid-sized pharmaceutical companies.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

New FDA leadership roles focused on technology and drugs open fresh avenues for regulatory engagement that could accelerate product approvals and compliance. Your pricing strategy needs adjustment as MFN deals signal rising pressure on drug prices and payments.

◆ Coverage

1 source · 27 Aug 2026

◆ Related on Wire

◆ Topics

Healthfda-leadershipdrug-pricingmfn-dealsus-health-policy